Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.

Publication

Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.

Journal Paper/Review - Jun 13, 2024

Gantenbein Andreas R, Bonvin Christophe, Kamm Christian Philipp, Schankin Christoph J, Zecca Chiara, Zieglgänsberger Dominik, Merki-Feld Gabriele Susanne, Pohl Heiko, Rudolph Nicole, Ryvlin Philippe, Agosti Reto, Schäfer Elisabeth, Meyer Ina, Kulartz-Schank Monika, Arzt Michael E

Citation

Gantenbein A, Bonvin C, Kamm C, Schankin C, Zecca C, Zieglgänsberger D, Merki-Feld G, Pohl H, Rudolph N, Ryvlin P, Agosti R, Schäfer E, Meyer I, Kulartz-Schank M, Arzt M. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. J Neurol 2024

Type

Journal Paper/Review (English)

Journal

J Neurol 2024

Publication Date

Jun 13, 2024

Issn Electronic

1432-1459

Brief description/objective

There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life.